AstraZeneca (AZN) Given a GBX 6,500 Price Target by Barclays Analysts

AstraZeneca (LON:AZN) has been assigned a GBX 6,500 ($87.21) price target by equities researchers at Barclays in a research report issued to clients and investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Barclays’ price objective would suggest a potential upside of 19.18% from the stock’s previous close.

A number of other equities analysts have also weighed in on AZN. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a research report on Friday, May 18th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 5,500 ($73.80) price objective on shares of AstraZeneca in a research report on Tuesday, May 15th. UBS set a GBX 4,550 ($61.05) price objective on shares of AstraZeneca and gave the company a “neutral” rating in a research report on Friday, May 18th. Berenberg Bank reiterated a “buy” rating and issued a GBX 6,000 ($80.50) price objective on shares of AstraZeneca in a research report on Friday, May 18th. Finally, Deutsche Bank reiterated a “buy” rating on shares of AstraZeneca in a research report on Monday. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of GBX 5,262.13 ($70.60).

AstraZeneca opened at GBX 5,454 ($73.18) on Tuesday, MarketBeat reports. AstraZeneca has a 1-year low of GBX 4,260 ($57.16) and a 1-year high of GBX 5,520 ($74.06).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply